Skip to main content

Table 5 Durvalumab-related adverse events

From: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

  Frequency %
Pneumonitis 6 25.0
G1 1 4.2
G2 3 12.5
G3 2 8.3